Serum cholinesterase (CHE) has been reported to be a significant indicator of liver function and prognosis in patients with cirrhosis. On the other hand, liver complications are frequent following allogeneic stem cell transplantation (HSCT). We therefore tested whether CHE was predictive of graft-versus-host disease and outcome in HSCT recipients. We studied 689 patients receiving a HSCT from an HLA-identical sibling (SIB) (n = 511), an alternative donor (n = 173) or a syngeneic twin (n = 5). Acute graft-versus-host disease (GVHD) was scored as 0-I, II, III-IV in 325 (47%), 279 (41%), and 85 patients (12%) respectively; 190 (28%) patients died of transplant-related complications (TRM). On day −7 the median CHE serum level was comparable in patients who either survived or died of TRM (5900 IU/l). On day 0, serum CHE levels were respectively 2310 and 2120 IU/l (P = NS) indicating the impact of the conditioning regimen. On day +7 after HSCT, the median level for surviving patients was 2598 IU/l vs 2309 IU/l for patients who subsequently died (P = 0.0002), on day +21 CHE levels were respectively 3348 vs 2528 IU/l (P Ͻ 0.00001), on day +50, 3575 vs 2358 IU/l (P Ͻ 0.00001) and on day +100 4193 vs 2729 IU/l (P Ͻ 0.00001). CHE levels on day +50 strongly correlated with aGVHD (3803 vs 3070 vs 1933 IU/l for patients with GVHD grade 0-I, II, and III-IV, respectively (P Ͻ 0.00001) and relapse (3569 for patients relapsing vs 3115 IU/l for patients not relapsing, P = 0.0006). In conclusion, (1) serum cholinesterase is a simple and reliable marker of acute GVHD and transplant-related complications; and (2) high CHE levels on day +50 predict relapse. If confirmed, the latter patients may be elegible for early reduction of immunosuppressive therapy. Bone Marrow Transplantation (2001) 28, 1041-1045.
There are two types of cholinesterase enzymes in the blood: acetylcholinesterase, found mainly in red blood cells (RBC) and butarylcholinesterase found in serum or plasma. 1 The in vivo substrate for both enzymes is acetylcholine, whereas in the laboratory acetylcholine or butarylcholine are used as substrates for the colorimetric reaction. 1 Butarylcholinesterase is also referred to as pseudo-cholinesterase or serum cholinesterase. 1 Serum cholinesterase (CHE) is synthesized by the liver immediately released into the plasma and is regenerated at a rate of 2% per day.
1,2 Serum CHE is used in gastroenterology as an indicator of liver synthetic capacity and patients with decreased serum CHE have a poor prognosis. 2, 3 In a study of patients with parenchymal liver cirrhosis, the median serum CHE levels for patients surviving 1 year was 2617 IU/l compared to 1737 for patients dead at 1 year (P = 0.002). 2 In a separate study, again in patients with cirrhosis, 2-year survival for patients with CHE levels greater than 2100 IU/l was 75% compared to 17% for patients with lower CHE levels (Ͻ2100 IU/l) (P = 0.001). 3 Therefore, serum CHE is a sensitive indicator of liver function and can be used to predict the outcome in patients with liver disease.
Liver disease is frequent after allogeneic hemopoietic stem cell transplantation (HSCT) as recently shown by the Working Party on Infectious Diseases of the European group for Blood and Marrow Transplantation (EBMT). 4 One hundred and ninety-three patients from 15 centers, grafted between January and June 1995, were entered in a prospective study designed to test the impact of hepatitis B (HBV) and C virus (HCV) infections on outcome. Fortythree patients died during the study period and liver disease was the main cause of death (13/43 = 30%). 4 The incidence of veno-occlusive disease (VOD) was 8%, fulminant hepatic failure 0.5% and 12% of cases had alanine aminotransferase (ALT) Ͼ500 U/l (normal р42 U/l); de novo HBV or HCV infections occurred in 3.2 and 7% of patients, respectively. Predictive risk factors for liver disease were unrelated donor transplants and abnormal donor ALT levels. 4 Other predictive factors for VOD have been published and include early increase in bilirubin levels and weight gain. 5 If serum CHE is an indicator of liver function and if liver disease is the primary cause of failure after an allogeneic HSCT, we asked the question: is serum CHE a predictor of outcome in recipients of an allogeneic HSCT? To answer this question we have studied 689 patients who received unmanipulated hemopoietic stem cell grafts (HSCT) between 1989 and 2000 in our unit, and have correlated CHE levels at different time-points from HSCT with graftversus-host disease (GVHD) and outcome.
Materials and methods

Data collection
Laboratory and clinical data have been collected prospectively since 1989, at least once a week from day −7 to day +30 and then at each assessment as an out-patient up to the last follow-up. This produces a dynamic data base with an unlimited number of records/patient. It gives the opportunity to look at laboratory tests at any given time pre-or post BMT, and correlate these tests with clinical outcome during the admission of patients to hospital and during examinations as out-patients. We focus in this study on cholinesterase expressed as international units (IU) per liter.
Patients
Six hundred and eighty-nine patients received an unmanipulated allogeneic HSCT between 1989 and 2000, from an HLA identical sibling (SIB) (n = 511), an alternative donor (n = 173) or a syngeneic twin (n = 5). Clinical data are outlined in Table 1 . Conditioning regimens included cyclophosphamide (CY) 120 mg/kg and total body irradiation (TBI) Graft-versus-host disease (GVHD) was scored according to the original Glucksberg clinical criteria. 6 GVHD prophylaxis consisted of cyclosporine (CsA) with or without methotrexate (MTX). CsA was given for at least 6 months with conventional tapering. Transplant protocols and management of patients have been described. 7 
Transplant-related mortality (TRM)
Transplant-related mortality (TRM) was defined as death due to any transplant-related complication. Thus patients experiencing relapse of the original disease were censored as surviving at the time of relapse.
Statistical analysis
The Mann-Whitney test was used for differences between continuous variables, and the Chi-square test for parametric variables. Survival curves were estimated according to Kaplan and Meier 8 and the log rank test was used to test for differences between curves. The Cox model was used to test for possible confounding factors. The statistical package was number cruncher (NCSS) 5.X series. Figure 1 outlines median levels of CHE in patients with acute GVHD grade 0-I, II and III-IV on days +7, +13, +21, +50 and +100. Patients without acute GVHD show a linear increase of CHE serum levels, whereas patients with grade II or grade III-IV GVHD not only fail to increase CHE levels, but tend to show decreasing levels. As shown in Figure 1 , serum CHE levels of patients' GVHD grade 0-I were different when compared to patients with GVHD grade II and grade III-IV on day +7 (respectively, P = 0.9 and P = 0.01), day +13 (P = 0.03 and P = 0.001), day +21 (both P Ͻ 0.0001) day +50 (both P Ͻ 0.0001) and day +100 (both P Ͻ 0.0001). Similarly CHE levels for patients with acute GVHD grade II were different when compared to patients with GVHD III-IV on day +7 (P = 0.02), +13 (P = 0.04), +21 (P Ͻ 0.0001), +50 (P Ͻ 0.0001), +100 (P Ͻ 0.0001). CHE levels on day +50 after transplant were highest in patients receiving a HSCT from a syngeneic twin (5155 IU/l), significantly more than HLA-identical sibling grafts (3536 IU/l) (P = 0.01) and alternative donor grafts (2893 IU/l) (P = 0.005). Patients receiving the combination of CsA + MTX had borderline higher CHE levels on day +50, as compared to patients receiving CsA alone (median levels 3438IU/l vs 3225 IU/l, P = 0.06).
Results
Cholinesterase (CHE) and GVHD
Cholinesterase (CHE) and transplant-related mortality (TRM)
Figure 2 outlines median CHE serum levels for patients surviving or not surviving the transplant. On day −7, CHE levels were 5900 IU/l in patients who survived or died of transplant-related complications. On day 0, serum CHE levels were 2310 and 2120 IU/l (P = NS) indicating the effect of the conditioning regimen. On day +7 after HSCT, the median level for surviving patients was 2598 IU/l vs 2309 IU/l for patients who subsequently died (P = 0.0002).
The difference became greater with time: on day +21 CHE levels were 3348 vs 2528 IU/l (P Ͻ 0.00001) on day +50, 3575 vs 2358 IU/l (P Ͻ 0.00001) and on day +100 4193 vs 2729 IU/l (P Ͻ 0.00001). On day +50, the 25 percentile was 2355 IU/l and the 75 percentile 4232 IU/l: the actuarial 6-year TRM for 100 patients with CHE levels of Ͻ2355 IU/l was 57%, vs 8% for patients with CHE levels Ͼ4232 IU/l and 29% for patients with intermediate CHE levels (P Ͻ 0.0001) (Figure 3 ). CHE levels on day +50 could subclassify patients with different grades of acute GVHD. As shown in Figure 4 , this was true for patients with GVHD grade 0-I in whom TRM ranged from 46% to 7% (P = 0.002) and for patients with GVHD grade II with TRM ranging from 43% to 7% (P = 0.007). For GVHD grade III-IV, there were no patients with CHE levels greater than 4000 IU/l and very Figure 3 Actuarial probability of transplant-related mortality (TRM) at 6 years in patients with day +50 serum CHE Ͻ2355 IU/l (A, 57%), CHE levels between 2355-4232 IU/l (B, 29%) and CHE greater than 4232 IU/l (C, 8%). A vs B: P = 0.003; A vs C: P Ͻ 0.00001; B vs C: P Ͻ 0.00001.
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Figure 4
Proportion of patients dying of transplant-related complications (TRM) after stratification according to acute GVHD grade 0-I (n = 191), grade II (n = 163) or grade III-IV (n = 46), and serum CHE on day +50 after HSCT (Ͻ2000, Ͻ3000, Ͻ4000, Ͻ11 000 IU/l). Serum CHE levels can identify patients with different risks of TRM within GVHD 0-I (P = 0.002) and GVHD grade II (P = 0.007). There is also a trend for a prognostic effect of CHE levels on TRM within patients with GVHD grade III-IV. This group has no patients with CHE levels Ͼ4000 IU/l. few with CHE levels greater than 3000 (n = 10). There was a trend for a different TRM in patients with different levels of CHE (P = 0.09).
Cholinesterase (CHE) and relapse
The median CHE levels on day +50 after HSCT were significantly higher in patients who subsequently relapsed (3569 IU/l) as compared to patients not relapsing (3115 IU/l; P = 0.0006). When stratifying patients according to median day +50 serum CHE levels Ͻ2000, Ͻ3000, Ͻ4000, Ͻ5000 and Ͻ11 000 IU/l, the proportion of patients with aGVHD grade III-IV was, respectively, 37%, 10%, 7%, 3%, 0% (P Ͻ 0.0001) and the proportion of patients who would subsequently relapse was 13%, 20%, 31%, 33%, 36% (P = 0.009) ( Figure 5 ).
Multivariate Cox analysis
A multivariate Cox analysis was also run to test for confounding factors such as donor type (HLA identical sibling vs alternative donors), donor and recipient gender and age, disease phase (early vs advanced), cells infused (×10 8 /kg), interval from diagnosis to transplant (in days), year of transplant and acute GVHD grade (0 to IV). Day +50 CHE levels still proved predictive for TRM (P Ͻ 0.00001) together with acute GVHD (P Ͻ 0.00001), donor group (P = 0.001), year of transplant (P = 0.004) and cells infused at transplant (P = 0.01). Serum CHE was also predictive of overall survival (P = 0.00001) together with acute GVHD (P Ͻ 0.00001) and donor type (P = 0.001).
Discussion
It has been reportedly recently that patients with grade II acute graft-versus-host disease (GVHD) and a platelet count greater than 50 × 10 9 /l on day +50 after HSCT, have a significantly lower risk of death (14%) as compared to patients with grade II GVHD, but a platelet count lower 
Figure 5
Correlation of day +50 serum CHE levels, relapse and GVHD grade III-IV. Increasing risk of relapse with increasing day +50 CHE levels (P = 0.006) and decreasing incidence of GVHD grade III-IV (P Ͻ 0.001).
than 50 × 10 9 /l (40%; P Ͻ 0.0001). 9 This finding suggests that, although different GVHD grades identify patients with different risk of TRM, 6 there is a heterogeneity of alloreactivity which is not picked up by the classical or revised GVHD scoring system. 6, 10 In addition we lack an objective laboratory marker, with the exception of bilirubin for liver GVHD, and the clinical scoring of acute GVHD may differ significantly from one observer to another. 11 This has led to a high rate of disagreement in clinical scoring of GVHD 11 and has called for revised clinical criteria.
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In a previous study, we have shown that blood urea nitrogen (BUN) was an early predictor of GVHD and transplant mortality, in addition to, and more significantly than bilirubin. 7 In the present study, we suggest that serum cholinesterase (CHE) is also an early and sensitive marker of GVHD, and of TRM. Highest CHE serum levels were detected in patients with no GVHD and/or patients receiving a syngeneic transplant. The difference in patients with or without acute GVHD is detectable soon after transplant, as early as day +7 and becomes more prominent with time. On day 13, there is a statistical difference between patients who will develop acute GVHD grade 0-I (median 2900 IU/l) vs grade II (median 2740 IU/l) (P = 0.03) vs acute GVHD grade III-IV (median 2430 IU/l) (P = 0.005). The difference in serum CHE levels becomes more prominent with time after transplant, and is highly significant on day +50 and day +100.
There is also a predictive effect of serum CHE levels on transplant-related mortality, which is not evident before transplant. Patients who will or will not die of transplantrelated complications have similar levels on day −7 and both exhibit an important reduction of serum CHE levels on the day of transplant (day 0), suggesting a toxic effect of chemo/radiotherapy on liver function. One week later patients who will survive the transplant have recovered significantly higher CHE levels compared to patients who will not survive, and the difference becomes greater with time.
However, why should serum CHE levels be such a good marker of GVHD, and therefore of TRM? The liver may be a good target of alloreactivity, and this is in keeping with the high incidence of liver complications after allogeneic HSCT. 4 If this is the case, then a sensitive indicator of liver synthetic capacity, such as serum CHE, would decrease rapidly following the conditioning regimen in all patients, but would recover rapidly only in patients free of significant graft-versus-host disease. This is what we have observed by correlating serum CHE levels with acute GVHD grading at different time-points post transplant. Some years ago, we published that serum transaminase (GPT) could be used as a marker of GVHD in patients receiving donor lymphocyte infusions (DLI), 13 and we are now analyzing a larger number of infusions showing that gamma glutamyl transferase (ggT) is a marker of GVHD after DLI.
14 Taken altogether, these data would suggest that liver function tests, in addition to bilirubin, can be used to mark alloreactivity, and serum CHE is one of them. Other markers may also be helpful to assess tissue integrity, such as diamine-oxidase which has been shown to correlate with intestinal mucosal injury. 15 One further question is whether serum CHE levels are also predictive when corrected for confounding factors, such as age, disease phase and donor type.
In multivariate analysis, day +50 serum CHE levels were the most significant predictor of transplant mortality and survival. The predictive value of day +50 serum CHE on alloreactivity, is further supported by the inverse correlation with acute GVHD and leukemia relapse. When patients were stratified according to day +50 serum CHE levels, the proportion of patients with aGVHD grade III-IV was 37% for CHE levels Ͻ2000 IU/l and 0% for CHE levels exceeding 4000 IU/l. Conversely, the proportion of patients who would subsequently relapse in the same two groups was 13% vs 36% and these two differences are highly significant.
If this is confirmed with other data sets, it may prove useful to modulate in vivo immune suppression. Patients with high serum CHE levels on day +50 after an allogeneic stem cell transplant are probably at low risk of acute GVHD and TRM, but have a significant probability of leukemia relapse. These patients may be eligible for early tapering of in vivo immunosuppression. In the setting of reduced intensity regimens, early tapering may be desirable but may also lead to GVHD and related mortality. 16 This being the case, it would not seem unreasonable to design a prospective clinical trial in patients with day +50 high serum CHE levels, to test rapid or conventional tapering of in vivo immunosuppression.
